04/22/2026
New results from a clinical trial led by DCI's Nicholas DeVito, MD, are the first to demonstrate the potential of immunotherapy by itself as the initial treatment for patients with the most common type of colorectal cancer.
https://duke.is/r/d9j6
| | Duke Health
DURHAM, N.C. – As colorectal cancer rates rise among young people, most patients with advanced disease still only have one treatment option: chemotherapy. That is rarely a cure, and often life-limiting with very toxic side effects.